Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/16/21
MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical PipelineBenzinga • 08/16/21
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical PipelinePRNewsWire • 08/13/21
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using TechnologyPRNewsWire • 08/03/21
MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 SubjectsBenzinga • 07/29/21
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual SummitPRNewsWire • 07/12/21
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity CompanyPRNewsWire • 07/08/21
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And MoreBenzinga • 06/30/21
Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics'Benzinga • 06/28/21